3 September 2020 - Consultation open on draft guidance until Friday 25 September 2020.

NICE has launched a second public consultation on its draft guidance which does not recommend a nasal spray medicine for treatment-resistant depression.

The committee concluded that the cost-effectiveness estimates for esketamine are much higher than what NICE normally considers a cost-effective use of NHS resources.

Read NICE press release